Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity

Role of CD47 in Hematological Malignancies

(2020) Entsar Eladl et al.   Journal of Hematology & Oncology

Targeting macrophage checkpoint inhibitor SIRPα for anticancer therapy

(2020) Jie Liu et al.   JCI Insight

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers

(2019) Branimir I. Sikic et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy.

(2019) Laura Quan Man Chow et al.   JOURNAL OF CLINICAL ONCOLOGY

SIRP α/ CD 47 axis controls the maintenance of transplant tolerance sustained by myeloid‐derived suppressor cells

(2019) Sabrina Pengam et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPα

(2019) Janet Sim et al.   mAbs

Tuning the Tumor Myeloid Microenvironment to Fight Cancer

(2019) Nadine S. Jahchan et al.   Frontiers in Immunology

A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma

(2019) Tae Min Kim et al.   BLOOD

Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα–CD47 innate immune checkpoint

(2019) Erik Voets et al.   Journal for ImmunoTherapy of Cancer

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

(2018) Frederick Arce Vargas et al.   CANCER CELL

CD47-signal regulatory protein α signaling system and its application to cancer immunotherapy

(2018) Yoji Murata et al.   CANCER SCIENCE

The Immune Landscape of Cancer

(2018) Vésteinn Thorsson et al.   IMMUNITY

4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses

(2018) Ashley V. Menk et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

SIRPα–CD47 Immune Checkpoint Blockade in Anticancer Therapy

(2018) André Veillette et al.   TRENDS IN IMMUNOLOGY

ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile

(2018) Steven E. Kauder et al.   PLoS One

Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion

(2018) Xiaojuan Liu et al.   Cell Reports

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12

(2018) Christopher S. Garris et al.   IMMUNITY

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

(2018) Ranjana Advani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer immunotherapy targeting the CD47/SIRPα axis

(2017) Kipp Weiskopf   EUROPEAN JOURNAL OF CANCER

Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross-priming through Signal Regulatory Protein α Signaling

(2017) Meng Michelle Xu et al.   IMMUNITY

The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer

(2017) Hanke L. Matlung et al.   IMMUNOLOGICAL REVIEWS

Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity

(2017) Nan Guo Ring et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding

(2016) Penka S. Petrova et al.   CLINICAL CANCER RESEARCH

Expression of heavy chain-only antibodies can support B-cell development in light chain knockout chickens

(2016) Benjamin Schusser et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses

(2016) Kelly D Moynihan et al.   NATURE MEDICINE

Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+T cells

(2016) Shu Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Durable antitumor responses to CD47 blockade require adaptive immune stimulation

(2016) Jonathan T. Sockolosky et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery

(2016) Suzanne I.S. Mosely et al.   Cancer Immunology Research

FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis

(2015) Rony Dahan et al.   CANCER CELL

Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect

(2015) David J. DiLillo et al.   CELL

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

(2015) Padmanee Sharma et al.   CELL

Cleavage of Signal Regulatory Protein α (SIRPα) Enhances Inflammatory Signaling

(2015) James D. Londino et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

CD47 blockade triggers T cell–mediated destruction of immunogenic tumors

(2015) Xiaojuan Liu et al.   NATURE MEDICINE

Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential

(2015) Jie Liu et al.   PLoS One

Engineered SIRP  Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies

(2013) K. Weiskopf et al.   SCIENCE

CD47-signal regulatory protein-  (SIRP ) interactions form a barrier for antibody-mediated tumor cell destruction

(2011) X. W. Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma

(2010) Mark P. Chao et al.   CELL

Batf3 Deficiency Reveals a Critical Role for CD8 + Dendritic Cells in Cytotoxic T Cell Immunity

(2008) K. Hildner et al.   SCIENCE